Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech Says Lucentis Cost Will Not Affect Access

This article was originally published in The Pink Sheet Daily

Executive Summary

The company recorded $10 million in Lucentis sales on the AMD therapy’s launch day.

You may also be interested in...



Lucentis’ First Patients Mostly Taken From Macugen, Visudyne & Avastin – Genentech

The company recorded $153 mil. in sales for the macular degeneration product in its first full quarter on the market.

Lucentis’ First Patients Mostly Taken From Macugen, Visudyne & Avastin – Genentech

The company recorded $153 mil. in sales for the macular degeneration product in its first full quarter on the market.

Genentech’s Lucentis Ships June 30 Following Approval

Ranibizumab, for the treatment of wet age-related macular degeneration, will be priced at a substantial premium to Pfizer/OSI's Macugen.

Topics

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel